Literature DB >> 17138245

Laboratory studies on pathophysiology of the catastrophic antiphospholipid syndrome.

Gerard Espinosa1, Silvia Bucciarelli, Ricard Cervera, José A Gómez-Puerta, Josep Font.   

Abstract

The 'catastrophic' variant of the antiphospholipid syndrome (APS) is characterized by a diffuse thrombotic microvasculopathy. In contrast to the classical APS, single venous or arterial medium-to-large blood vessel occlusions are uncommon. The mechanisms of catastrophic APS are not clearly understood. In addition, there are no studies on pathophysiologic mechanisms of catastrophic APS. The clinical manifestations of catastrophic APS probably depend on (a) the organs affected by the thrombotic events and extent of the thrombosis and (b) manifestations of the systemic inflammatory response syndrome which are presumed to be due to excessive cytokine release from affected and necrotic tissues. The evident relationship between APS and infection may enable us to explain the development of catastrophic APS using the sepsis model. This is because catastrophic APS is characterized by multiple microvascular thrombotic events, of rapid onset, and causing multiorgan failure, a picture suggestive of septic shock, in which, there is a massive, acute inflammatory response.

Entities:  

Mesh:

Year:  2006        PMID: 17138245     DOI: 10.1016/j.autrev.2006.06.006

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  5 in total

Review 1.  Treatment of catastrophic antiphospholipid syndrome.

Authors:  Nayef M Kazzaz; W Joseph McCune; Jason S Knight
Journal:  Curr Opin Rheumatol       Date:  2016-05       Impact factor: 5.006

Review 2.  Probable Catastrophic Antiphospholipid Syndrome with Intracerebral Hemorrhage Secondary to Epstein-Barr Viral Infection.

Authors:  Mark P Plummer; Adam M H Young; Ronan O'Leary; Maxwell S Damian; Andrea Lavinio
Journal:  Neurocrit Care       Date:  2018-02       Impact factor: 3.210

3.  Catastrophic antiphospholipid syndrome presented with abdominal, pulmonary, and bone marrow complications.

Authors:  Badira F Makhoul; Ludmila Guralnik; Zaher S Azzam
Journal:  Rheumatol Int       Date:  2009-05-18       Impact factor: 2.631

4.  The complex treatment including rituximab in the Management of Catastrophic Antiphospholid Syndrome with renal involvement.

Authors:  Aleksandra Rymarz; Stanisław Niemczyk
Journal:  BMC Nephrol       Date:  2018-06-08       Impact factor: 2.388

Review 5.  The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome.

Authors:  Cristina Rosário; Gisele Zandman-Goddard; Esther G Meyron-Holtz; David P D'Cruz; Yehuda Shoenfeld
Journal:  BMC Med       Date:  2013-08-22       Impact factor: 8.775

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.